8.40
price down icon13.85%   -1.35
pre-market  Pre-mercato:  8.44   0.04   +0.48%
loading
Precedente Chiudi:
$9.75
Aprire:
$9.68
Volume 24 ore:
1.36M
Relative Volume:
1.99
Capitalizzazione di mercato:
$646.92M
Reddito:
-
Utile/perdita netta:
$-209.96M
Rapporto P/E:
-2.6582
EPS:
-3.16
Flusso di cassa netto:
$-176.27M
1 W Prestazione:
-21.42%
1M Prestazione:
-33.75%
6M Prestazione:
-29.41%
1 anno Prestazione:
+8.67%
Intervallo 1D:
Value
$8.36
$9.68
Intervallo di 1 settimana:
Value
$8.36
$10.78
Portata 52W:
Value
$4.92
$17.00

Replimune Group Inc Stock (REPL) Company Profile

Name
Nome
Replimune Group Inc
Name
Telefono
(781) 222-9600
Name
Indirizzo
500 UNICORN PARK, WOBURN, MA
Name
Dipendente
331
Name
Cinguettio
@Replimune
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
REPL's Discussions on Twitter

Confronta REPL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
REPL
Replimune Group Inc
8.40 646.92M 0 -209.96M -176.27M -3.16
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-28 Iniziato ROTH MKM Buy
2023-04-17 Ripresa Piper Sandler Overweight
2021-11-19 Iniziato Piper Sandler Overweight
2021-10-15 Ripresa BTIG Research Buy
2020-11-17 Iniziato BTIG Research Buy
2020-11-02 Iniziato Jefferies Buy
2020-10-15 Aggiornamento H.C. Wainwright Neutral → Buy
2020-07-01 Downgrade H.C. Wainwright Buy → Neutral
2020-05-05 Iniziato Barclays Overweight
2019-09-04 Iniziato ROTH Capital Buy
2019-07-23 Iniziato Chardan Capital Markets Buy
2019-07-12 Aggiornamento JP Morgan Neutral → Overweight
2019-07-08 Iniziato H.C. Wainwright Buy
2019-04-25 Iniziato Wedbush Outperform
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-08-14 Iniziato JP Morgan Overweight
2018-08-14 Iniziato Leerink Partners Outperform
Mostra tutto

Replimune Group Inc Borsa (REPL) Ultime notizie

pulisher
Mar 30, 2025

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Swiss National Bank - Defense World

Mar 30, 2025
pulisher
Mar 25, 2025

Charles Schwab Investment Management Inc. Has $6.16 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 25, 2025
pulisher
Mar 22, 2025

Victory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Bank of New York Mellon Corp Increases Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Holdings Cut by AlphaQuest LLC - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Average Price Target from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 17, 2025

Arizona State Retirement System Invests $156,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 17, 2025
pulisher
Mar 12, 2025

Financial Metrics Check: Replimune Group Inc (REPL)’s Ratios for Trailing Twelve Months - The Dwinnex

Mar 12, 2025
pulisher
Mar 07, 2025

Replimune Group Appoints New Director, Grants Stock Options By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Replimune Group Appoints New Director, Grants Stock Options - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Replimune Group Appoints Michael Goller To Board, Increases Board Size To Ten -March 07, 2025 at 05:04 pm EST - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 07, 2025
pulisher
Mar 07, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -March 07, 2025 at 04:11 pm EST - Marketscreener.com

Mar 07, 2025
pulisher
Mar 06, 2025

Rhumbline Advisers Grows Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital

Mar 06, 2025
pulisher
Mar 05, 2025

New York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 05, 2025
pulisher
Mar 01, 2025

JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World

Mar 01, 2025
pulisher
Feb 24, 2025

Replimune Group (NASDAQ:REPL) Stock Price Up 6.1%What's Next? - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from Brokerages - Defense World

Feb 23, 2025
pulisher
Feb 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update - MarketBeat

Feb 20, 2025
pulisher
Feb 18, 2025

Replimune's SWOT analysis: oncolytic immunotherapy stock poised for FDA approval - Investing.com

Feb 18, 2025
pulisher
Feb 17, 2025

Possible Bearish Signals With Replimune Group Insiders Disposing Stock - Simply Wall St

Feb 17, 2025
pulisher
Feb 17, 2025

Leerink Partnrs Predicts Weaker Earnings for Replimune Group - Defense World

Feb 17, 2025
pulisher
Feb 17, 2025

FY2025 EPS Estimates for Replimune Group Lowered by Wedbush - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results - MarketBeat

Feb 17, 2025
pulisher
Feb 16, 2025

HC Wainwright Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat

Feb 16, 2025
pulisher
Feb 14, 2025

Replimune stock target raised to $22 at H.C. Wainwright - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Replimune stock target raised to $22 at H.C. Wainwright By Investing.com - Investing.com Australia

Feb 13, 2025
pulisher
Feb 12, 2025

Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL) - Seeking Alpha

Feb 12, 2025
pulisher
Feb 12, 2025

Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Replimune Group Inc. (REPL) reports earnings - Quartz

Feb 12, 2025
pulisher
Feb 12, 2025

Replimune Group, Inc. SEC 10-Q Report - TradingView

Feb 12, 2025
pulisher
Feb 12, 2025

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

FDA Fast-Tracks Replimune's Melanoma Treatment as Cash Reserves Hit $536M in Q3 Report - StockTitan

Feb 12, 2025
pulisher
Feb 10, 2025

Top Wealth Group Holding Ltd (TWG)’s financial ratios: A comprehensive overview - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Metric Analysis: Nvni Group Ltd (NVNI)’s Key Ratios in the Limelight - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Feb 10, 2025
pulisher
Feb 08, 2025

How to Take Advantage of moves in (REPL) - Stock Traders Daily

Feb 08, 2025

Replimune Group Inc Azioni (REPL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Capitalizzazione:     |  Volume (24 ore):